Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatment
Chemotherapy receipt is high in BRCA1/2 and PALB2-associated breast cancers including in early stage, node-negative disease. Pre-diagnostic awareness is associated with a lower likelihood of requiring chemotherapy for a breast cancer diagnosis.
Authors
- Stephanie M. Wong (ORCID: https://orcid.org/0000-0002-6850-2192)
- Sarkis Meterissian (ORCID: https://orcid.org/0000-0002-9586-3583)
- Carla Apostolova
- William D. Foulkes (ORCID: https://orcid.org/0000-0001-7427-4651)
- Ipshita Prakash (ORCID: https://orcid.org/0000-0002-0730-5363)
- Mark Basik (ORCID: https://orcid.org/0000-0002-2633-5410)
- Basmah Alhassan
- Talía Malagón (ORCID: https://orcid.org/0000-0002-9505-3564)
- Nora Wong
- Michaela Bercovitch Sadinsky (ORCID: https://orcid.org/0000-0002-1592-9467)
- Amina Ferroum
- David Fleiszer (ORCID: https://orcid.org/0000-0003-3561-3731)
- Jean Francois Boileau
- Karyne Martel
Institutions
- Jewish General Hospital (CA)
- McGill University (CA)
Publication Details
- Journal
- Hereditary Cancer in Clinical Practice
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s13053-025-00314-x
- Citations
- 2
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Fonds de Recherche du Québec - Santé